HydroVax-CHIKV: a first-in-human vaccine against chikungunya for adults and at-risk groups
Official title: A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine
Funded at Najit Technologies, INC. · NIH-11384503 · Data updated 2026-11-12
A first-in-human phase I trial tests a new inactivated chikungunya vaccine to see if it is safe and prompts an immune response in adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Najit Technologies, INC. NIH-funded |
| Lab location | 1 site (Beaverton, UNITED STATES) |
| Project start | July 1, 2020 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $980,257 |
| NIH project number | 5U44AI152995-04 |
| Project ID | NIH-11384503 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years and older who meet the study criteria and consent to participate.
✕Less likely to help
Some participants may not experience direct benefit and could experience vaccine-related side effects.
What this research studies
This study will enroll adults to receive different doses of HydroVax-CHIKV or a placebo in a double-blind setup. Researchers will monitor safety, adverse events, and preliminary immune responses after vaccination. The trial design aims to identify a dose with acceptable safety and potential protective immunity for future studies in broader populations, including vulnerable groups. If successful, this work could lay the groundwork for a vaccine option against chikungunya for people living in affected regions.
Why it matters
Potential benefit: If successful, participants could contribute to the development of a vaccine that may protect against chikungunya in the future.
How similar studies have gone: Previous chikungunya vaccine efforts have shown varying safety profiles and immunogenicity in early trials, with continued exploration needed.
Where this research is happening
-
Najit Technologies, INC.
Beaverton, United States Active
Researchers
- Principal investigator: Amanna, Ian James — Najit Technologies, INC.
- Study coordinator: Amanna, Ian James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.